Clinical trials and the COVID-19 pandemic

Area of Science:

• Medical History
• Clinical Trials
• Medical Ethics

Background:

• The randomized trial is the gold standard for evaluating novel therapies, particularly in cancer research.
• However, its application in critical situations like pandemics raises ethical concerns regarding patient consent and equitable treatment allocation.
• Historical experiments, such as Galen's on Theriac, demonstrate early forms of empirical investigation preceding modern randomized trials.

Purpose of the Study:

• To explore the historical evolution and ethical considerations of the randomized trial.
• To examine the challenges posed by randomized trials during the COVID-19 pandemic.
• To advocate for a more humane approach in clinical research, balancing scientific rigor with ethical imperatives.

Main Methods:

• Historical analysis of early experimental methods (e.g., Galen's experiments).
• Discussion of ethical principles from the Declaration of Helsinki.
• Examination of contemporary challenges in randomized clinical trials during the COVID-19 pandemic.

Main Results:

• Galen's experiments with Theriac in roosters predated modern randomized trials by centuries, showcasing early scientific methodology.
• The COVID-19 pandemic highlighted ethical dilemmas in treatment allocation and patient consent within randomized trials.
• The rigid adherence to randomized trials may overlook valuable insights from non-randomized studies and humanistic considerations.

Conclusions:

• While randomized trials are crucial for scientific rigor, ethical considerations, especially during pandemics, necessitate a more flexible and humane approach.
• The historical perspective reveals that scientific inquiry has evolved, and future methods may offer alternatives to current randomized trial paradigms.
• Balancing the pursuit of new knowledge with the rights and well-being of individual patients remains paramount, echoing the principles of the Hippocratic tradition.